Polythiazide


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Oedema Initial: 1-4 mg once daily in the morning. HTN 2-4 mg once daily.
Dosage Details
Oral
Hypertension
Adult: 2-4 mg once daily.

Oral
Oedema
Adult: Initially, 1-4 mg once daily in the morning.
Contraindications
Hypersensitivity to sulfonamide-derived drugs, anuria.
Special Precautions
Patient w/ fluid and electrolyte imbalance, history of bronchial asthma, gout, DM. May exacerbate SLE. Hepatic and renal impairment. Pregnancy and lactation.
Adverse Reactions
Anorexia, gastric irritation, nausea, vomiting, cramping, diarrhoea, constipation, jaundice, pancreatitis, dizziness, vertigo, paraesthesias, headache, xanthopsia, leukopenia, agranulocytosis, thrombocytopenia, aplastic anaemia, purpura, photosensitivity, rash, urticaria, necrotising angiitis, orthostatic hypotension, electrolyte imbalance, hyperglycaemia, glycosuria, hyperuricaemia, muscle spasm, weakness, restlessness.
MonitoringParameters
Determination of serum electrolytes to detect possible electrolyte imbalance should be performed at appropriate intervals.
Drug Interactions
May increase the risk of lithium toxicity. Hypokalaemia may develop w/ concomitant use of corticosteroids or ACTH. May augment the paralyzing actions of tubocurarine and decrease arterial responsiveness to norepinephrine. May alter antidiabetic dosing. Orthostatic hypotension may be aggravated w/ barbiturates or narcotics. Metabolic effects of hypokalaemia may be increased w/ concomitant digitalis therapy.
Lab Interference
May alter laboratory test results for K, BUN, glucose, and protein-bound iodine (PBI).
Action
Description: Polythiazide reduces the reabsorption of electrolytes from the renal tubules, thereby increasing the excretion of Na and Cl ions and consequently of water. It also reduces the GFR.
Onset: Approx 2 hr.
Duration: 24-48 hr.
Pharmacokinetics:
Absorption: Readily absorbed from the GI tract.
Distribution: Plasma protein binding: >80%.
Excretion: Via urine (as unchanged drug) and faeces. Elimination half-life: Approx 26 hr.
Storage
Store between 20-25°C.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Polythiazide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in